SCCM Resource Library-Pulse Methylprednisolone Versus Dexamethasone in COVID-19: A Multicenter Cohort Study

Pulse Methylprednisolone Versus Dexamethasone in COVID-19: A Multicenter Cohort Study

Video Transcription

Video Summary

In this video, Atsuyuki Watanabe presents a study comparing the effectiveness of Pulse Methylprednisolone (MTP-Pulse therapy) and dexamethasone in treating COVID-19 patients. The study used a multi-century inpatient claim database in Japan and included over 7,800 patients. The results showed that MTP-Pulse therapy was associated with higher risks of in-hospital mortality, hyperglycemia, and longer hospital stay compared to dexamethasone. The study also found that MTP-Pulse was not associated with improved mortality, even in patients on mechanical ventilation. The findings emphasize the importance of considering the potential benefits and risks of different corticosteroid treatments for COVID-19 patients.

Asset Subtitle

Research, Infection, 2023

Asset Caption

Type: star research | Star Research Presentations: Infectious Disease (SessionID 30012)

Meta Tag

Content Type Presentation

Knowledge Area Research

Knowledge Area Infection

Membership Level Professional

Membership Level Select

Tag Outcomes Research

Tag COVID-19

Year 2023

Keywords

Atsuyuki Watanabe

Pulse Methylprednisolone

MTP-Pulse therapy

dexamethasone

COVID-19 treatment

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.